DIA’s Conference on clinical trial endpoints will bring together key stakeholders to address critical questions and generate potential solutions to challenges associated with determining study endpoints and outcomes. The 2018 Conference will examine global strategies for selecting study endpoints, and the impact of study endpoints during analysis of clinical evidence in the various types of drug approval processes. Hear from regulators, payers, patients, measurement experts, and others, as we navigate the complexities of developing and employing appropriate patient-focused endpoints for use in clinical trials. Discussions will cover the use of exit interviews, considerations for time to deterioration endpoints, and navigating the challenges of endpoints in small samples with heterogeneity, among other important topics that are critical across a broad set of stakeholders.
This program has been developed in collaboration with the Study Endpoints Community.
Want more on study endpoints? Check out two key sessions from the DIA 2018 Global Annual Meeting to get the latest on digital/mobile technology in clinical trials, and patient-focused outcomes. Download Sessions
Want to learn more about Advancing the Science of Study Endpoints? You've come to the right site!
René Allard, PhD Contractor
Emuella Flood Director, Patient-Reported Outcomes
AstraZeneca, United States
J. Jason Lundy, PhD Principal
Outcometrix, United States
Matthew Reaney, PhD, MSc Head of Science and Analytics, Patient Centered Solutions
IQVIA, United Kingdom
Ashley F. Slagle, PhD, MS Principal, Scientific and Regulatory Consulting
Aspen Consulting, LLC, United States
Keith Wenzel Volunteer
DIA Study Endpoints Community, United States
Michael Lees, MA Chief Operating Officer and Head of Market Access Strategy
PHMR Ltd, United Kingdom
Have an account?